Advanced MRI Imaging Services

We offer advanced MRI services that produce clear, high-resolution brain images without the use of radiation. Our hospital-grade scanners provide detailed anatomical and functional views of the brain. Using functional MRI (fMRI), we capture how different regions respond during rest or activity, helping to evaluate brain function and support faster, more accurate diagnosis. At ZRO, our neuro-focused MRI technology gives doctors and researchers the capability to detect abnormalities early and optimize care strategies.

DTI is an advanced MRI technique that maps the diffusion of water molecules to visualize white matter connections in the brain. It is particularly useful for detecting subtle changes associated with Alzheimer’s disease and related neurodegenerative disorders. At ZRO, our detailed DTI maps help clinicians and researchers identify early abnormalities missed by conventional MRI, accelerate research timelines, and support both diagnostic and therapeuticdecisions.

Resting-state fMRI measures spontaneous brain activity while patients lie in the MRI scanner without performing any specific tasks. This approach highlights functional connectivity patterns across brain regions, revealing disruptions associated with Alzheimer’s disease and other neurodegenerative conditions. At ZRO, we use rs-fMRI to evaluate brain network function in a non-invasive way, providing valuable data for both clinical and research purposes.

ASL is a non-invasive MRI technique that measures cerebral blood flow without contrast injections. It provides quantitative insight into blood vessels, perfusion, and oxygenation across brain tissue. These metrics help detect vascular abnormalities and monitor disease progression in Alzheimer’s and related conditions. At ZRO, we use ASL to support precise diagnosis and research, helping to evaluate perfusion changes safely and effectively.

SWI detects subtle changes in brain tissue density, such as microbleeds, iron accumulation, and small vascular abnormalities. These findings are relevant in conditions like Alzheimer’s disease, where traditional MRI may miss early changes. At ZRO, we use SWI to provide high-resolution insight into brain pathology, improving early detection and supporting long-term monitoring.

T1 and T2 mapping are quantitative MRI techniques that measure brain tissue properties with high precision. These methods detect subtle changes linked to neurodegeneration, including tissue loss, inflammation, or demyelination. At ZRO, we use T1 and T2 maps to support early detection, diagnostic imaging, and therapy monitoring. Combined with other advanced MRI modalities, they give a three-dimensional and multi-modal perspective on brain health.

ZRO provides comprehensive neuroimaging services, from MRI scanning to advanced data processing and statistical analysis. Our workflow ensures comfort for participants while capturing both structural and functional brain data. Researchers and clinical partners rely on us for state-of-the-art imaging in studies of Alzheimer’s disease, tumors, stroke, and other brain disorders.

At ZRO, we integrate MRI with molecular imaging techniques such as PET, as well as CT, ultrasound, and x-ray, to capture both brain structure and cellular activity. This multimodal approach enhances early detection, supports intervention planning, and enables precise image-guidance for research and clinical applications. By combining modalities, we offer a complete view of brain health and disease progression.

Our MRI services support a wide range of research and clinical uses, including:

• Brain mapping for functional, anatomical, and diagnostic imaging of neurol
• Biomarker development for diagnostic and therapeutic trials in neurodegener
• Clinical trial endpoint support with standardized MRI, CT, and molecular imaging protocols plus quantitative

At ZRO, we deliver high-quality, brain-focused MRI services with precision and consistency. Our expert team and advanced technology ensure reliable, research-grade imaging for every scan. We support clinicians, researchers, and clinical trial sponsors with clear, actionable data—contributing to better care and deeper understanding of neurodegenerative diseases such as Alzheimer’s, PSP, and related conditions.

Short-lived radiolabeled compounds such as carbon-11 or oxygen-15 require expert handling. Our integrated radiochemistry and imaging workflows enable rapid synthesis, seamless transfer, and precise scanning — ideal for preclinical and early-phase human trials with fast-clearing brain tracers. This ensures high-quality, reproducible molecular imaging data and accurate measurement of brain uptake with high sensitivity.